Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety and Immunogenicity of SCB 2019, a Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine for COVID-19 in Healthy Volunteers.
NCT04405908 is registered in ClinicalTrials.gov with Clover Biopharmaceuticals AUS Pty as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety and Immunogenicity of SCB 2019, a Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine for COVID-19 in Healthy Volunteers.
- Lead sponsor
- Clover Biopharmaceuticals AUS Pty
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 19, 2020
- Completion date
- December 8, 2021
- Enrollment
- 166 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.